VIJAYANSE29 May 2023

Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation

Vijaya Diagnostic Centre Limited

May 29, 2023

To, Listing Department National Stock Exchange Of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400 051 NSE Symbol. VIJAYA

To, The Corporate Relations Department BSE Limited, Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, Mumbai - 400 001 BSE Scrip Code. 543350

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation for Q4 & FY 2023 results and which would be used in the Investors / Analysts earnings conference call scheduled to be held on May 30, 2023 at 12:00 Noon IST.

Please take the information on record.

Thanking you, For Vijaya Diagnostic Centre Limited

Hansraj Singh Company Secretary & Compliance Officer M. No. F11438

Encl.: As Above

HANSRAJ SINGHDigitally signed by HANSRAJ SINGH Date: 2023.05.29 20:55:37 +05'30' Vijaya Diagnostic Centre Limited

Q4 & FY23 Earnings Presentation

May 29, 2023

Safe Harbour

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vijaya Diagnostic Centre Limited (the ‘Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Q4 & FY23 Financial Performance

Notes to Financial Results

Change in Accounting Estimate:

“ With effect from 01 January 2023, the Company has changed its method of depreciation on all Property, Plant and Equipment from Written Down Value (“WDV") method to Straight Line Method (“SLM"), based upon the technical assessment of expected pattern of consumption of the future economic benefits embodied in the assets.

Due to the aforesaid change, the depreciation expense is lower by Rs. 90.4 Mn and PAT is higher by Rs. 67.7 Mn for the quarter ended and year ended March 31, 2023. There has been no change in the depreciation expense recognised up to the period ended December 31, 2022."

Q4 FY23 – Performance Snapshot

Operational & Financial Highlights – Q4 FY23

2.71 Mn Tests

0.80 Mn Footfalls

121 Centres (opened 5 closed 1)

94.8% B2C Revenue

INR 1,209.9 Mn Revenue from operations

INR 1,203.1 Mn Non-COVID Revenue2

+22.4%

+24.7%

Non COVID Revenue growth (YoY)

Non COVID test volume growth (YoY)

INR 491.1 Mn EBIDTA

40.6% EBIDTA Margin

INR 275.0 Mn Profit After Tax1

22.7% PAT Margin

Note 1: Refer Slide no. 4 Note 2 : Non-COVID revenues constituted 99% of the Revenue from operations in Q4FY23

INR 1 per Share Dividend

Management comment

Commenting on the Q4FY23 results performance, Ms. Suprita Reddy, CEO at Vijaya Diagnostic Centre Ltd. said:

"We are extremely delighted to announce that Q4 witnessed stellar performance, with achievement of the highest ever quarterly Non-COVID revenue growth of 22.4% year-on-year. This was characterized by strong performance in both radiology and pathology segments, reinforcing the strength of our integrated model.

We consistently maintained our expansion momentum this quarter, expanding by 2 new hubs, 1 spoke and 2 mini spokes, taking the total centre count to 121. A noteworthy achievement during the quarter was the successful inauguration of VDCL’s state-of-the- art facility in Tirupati, Andhra Pradesh. Despite it being a relatively new location, we are glad to share that the customer response and the acceptance of our brand has been phenomenal.

It is a thing of great joy and pride that our Rajahmundry and Punjagutta hubs have demonstrated consistent performance amidst immense competition in the diagnostic space and achieved an operating break-even within an extremely short span of just two to three quarters from commencement of operations.

The recently implemented comprehensive LIMS has successfully stabilized and is being effortlessly used across all our centres. This marks the fulfilment of a crucial milestone, enabling us to streamline operations and enhance efficiency on a larger scale, across our vast network of centres.

Taking progressively steady strides towards patient convenience and a holistic patient experience, we have successfully built and launched a robust and easy-to-use mobile app that significantly enhances the overall patient experience. It is available for all test types, both in radiology and pathology alike, making it one-of-a-kind in the diagnostic space. This all-encompassing app is available for both iOS & Android. The company has also completed the successful roll-out of a fully functional e-commerce website.

Our informed strategy of digital transformation, market research backed approach for new market expansion and concentration on enhancement of our network of centres will ensure sustainable year-on-year growth. We aim to adopt the highest standards of quality and to deliver a holistic customer experience whilst employing the most advanced technology and we firmly believe that this will enable us make the most of the ever evolving opportunity for growth in the diagnostic space.”

Key Financial Highlights – Q4 & FY23

(INR Mn)

Revenue from Operations

EBITDA & EBITDA Margin (%)

4,624

4,592

41.2%

39.1%

40.6%

44.1%

39.6%

2,037

1,820

1,162

1,131

1,210

479

443

491

Q4 FY22

Q3 FY23

Q4 FY23

FY22

FY23

Q4 FY22

Q3 FY23

Q4 FY23

FY22

FY23

Shift YoY (%)

4.1%

-0.7%

2.6%

-10.6%

PAT & PAT Margin (%)

20.4%

14.5%

22.7%

23.7% 1,097

18.4%

846

237

164

275

Q4 FY22

Q3 FY23

Q4 FY23

FY22

FY23

15.9%

-22.8%

Shift YoY (%)

Note: Refer Slide no. 4

Revenue Mix – Q4 & FY23

(in %)

Radiology vs. Pathology Breakdown

Non-COVID & COVID Allied Breakdown

Radiology

Pathology

Non Covid

Covid

69%

31%

64%

67%

65%

36%

33%

Q4 FY22

Q3 FY23

Q4 FY23

FY22

35%

FY23

15%

85%

99%

Q4 FY22

Q3 FY23

Q4 FY23

Non-COVID YoY (%)

COVID YoY (%)

22.4%

-96.2%

B2C Contribution

Non Covid

Covid

B2B 5%

B2C 95%

Q4 FY23

B2B 5%

B2C 95%

FY23

15%

85%

FY22

Non-COVID YoY (%)

COVID YoY (%)

98%

FY23

14.7%

-88.0%

Q4 & FY23 – Key Developments

Tirupati Facility

Rajahmundry Facility

Panjagutta Facility

Inaugurated a state-of-the-art hub in Tirupati, Andhra Pradesh

• Q4FY23 marked the successful inauguration of more than 10,000 Sq. ft advanced and fully equipped facility in Tirupati, Andhra

Pradesh.

• Commencing full-fledged operations in May 2023, this state-of-the-art hub offers advanced radiology investigations and

houses top-class equipment such as a 3T MRI, CT, Gamma Camera and an automated lab.

Achieved operational break-even in Rajahmundry and Panjagutta in record 6 - 9 months from commissioning

• Vijaya inaugurated its 10,000 Sq. ft. state-of-the-art facility in Rajahmundry in August 2022. This hub, equipped to offer a wide range of integrated diagnostic services in the Godavari region of Andhra Pradesh successfully achieved an operational break- even in a very short span of just three quarters from commencement of operations.

• Commencing operations in Nov-22, Vijaya’s mammoth 16,000 Sq. Ft. facility in Panjagutta, Hyderabad achieved an operational break-even in a mere 6 months. This centre is one-of-a-kind in the whole of South India and has advanced technologies like 'Walk-in Walk-out Dual source CT' and 'BioMatrix 3T', besides other cutting-edge radiology equipment such as 'PET CT' and 'Gamma Camera'.

Stabilized the recently implemented LIMS software and successfully launched a robust mobile app and an E-commerce website

•

The recently implemented comprehensive LIMS has comfortably blended into the system and is being used effortlessly across all centres.

• We have successfully built and launched a robust, easy-to-use mobile app that is available for all test types in radiology and

pathology. A fully functional e-commerce website was also developed and rolled out.

Q4 & FY23 – Key Developments

Continued positive momentum witnessed in operational performance

On the back of healthy traction seen in Non-COVID business across

all segments, - the Company witnessed year-on-year as well as

quarter-on-quarter improvements in Non-COVID test volumes

during Q4FY23

Non-COVID Test Volumes (# in Million)

2.57

2.48

2.70

2.18

Q1 FY23

Q2 FY23

Q3 FY23

Q4 FY23

Q4 & FY23 - Financial and Operational Discussions (Y-o-Y)

Financial Performance Q4FY23

Financial Performance FY23

•

Revenue from Operations increased by 4.1% YoY to Rs. 1,210 Mn, Non-Covid Revenues grew by 22.4% YoY

o The Non-COVID growth was driven by both radiology and pathology segments, highlighting the strength of our

integrated model.

o During Q4FY23, the Non-COVID business comprised 99% of total revenue share as against 85% revenue share in Q4FY22

•

o Wellness share in Q4FY23 was up at 13.4% as against 8.4% in Q4FY22

o Revenue composition from B2C segment stood at 94.8%

EBITDA stood at Rs. 491 Mn. EBITDA margin for the quarter was 40.6% as against 41.2% in Q4FY22

o Despite opening new facilities, the Company managed to successfully maintain its margin performance on a Y-o-Y basis

PAT stood at Rs. 275 Mn. translating into a PAT margin of 22.7% (refer “Notes to Financial Results” in Slide no. 4)

Revenue from Operations stood at Rs. 4,592 Mn as against Rs. 4,624 Mn in FY22, Non-Covid Revenues grew by 14.7% YoY

o Wellness share in FY23 was up at 12.1% as against 6.8% in FY22

o Revenue composition from B2C segment continued to stay strong at 95%

EBITDA stood at Rs. 1,820 Mn. EBITDA margin for FY23 was 39.6%

PAT stood at Rs. 846 Mn. translating into a PAT margin of 18.4% in FY23 (refer “Notes to Financial Results” on Slide no. 4)

Key Financial Highlights

Cash flow from Operations / EBITDA (%)

Cash & Cash Equivalents (INR Mn)

90.7%

89.8%

74.2%

77.4%

2,466

2,425

2,554

2,466

2,554

Q4FY22

Q3FY23

Q4FY23

FY22

FY23

Q4 FY22

Q3 FY23

Q4 FY23

FY22

FY23

Working Capital Days1

• Cash flow from Operations stood at Rs. 1,646 mn.

Q4FY22

Q3FY23

Q4FY23

FY22

FY23

for 12M ended March 31, 2023

-6

-10

-13

• Cash and Cash Equivalents stood at Rs. 2,554 mn.

as on March 31, 2023

• Working Capital Days negative at -13 in Q4FY23

continues

to remain

Note: Quarterly Revenue figures are annualized

Key Operational Highlights

Tests Performed (# in Million)

Footfalls (# in Million)

Tests / Footfalls (# in Million)

9.32

10.05

3.62

3.18

3.22

3.37

3.17

2.57

2.55

2.45

2.49

2.71

0.96

0.77

0.80

Q4 FY22

Q3 FY23

Q4 FY23

FY22

FY23

Q4 FY22

Q3 FY23

Q4 FY23

FY22

FY23

Q4 FY22

Q3 FY23

Q4 FY23

FY22

FY23

Revenue per Test (INR)

496

474

454

447

457

Revenue per Footfall (INR)

1,212

1,464

1,504

1,276

1,446

Q4 FY22

Q3 FY23

Q4 FY23

FY22

FY23

Q4 FY22

Q3 FY23

Q4 FY23

FY22

FY23

• Company recorded steady growth in No. of tests on YoY basis led by Non-COVID customers in FY23

Consolidated Profit & Loss Account – Q4 & FY23

(INR Mn)

Particulars

Q4 FY23

Q4 FY22

Revenue from operations

1,209.9

1,162.0

Cost of materials consumed

Employee benefits expense

Other expenses

EBITDA

EBITDA Margin (%)

Other income

Depreciation and amortization expense

EBIT

Finance costs

Profit before Tax

Tax expenses

Profit before Minority Interest

Minority Interest

Profit after Tax (PAT)

PAT Margin (%)

EPS – Basic (INR)*

Note: Refer Slide no. 4

155.3

195.5

368.3

490.8

178.8

192.0

312.7

478.6

40.6%

41.2%

45.2

113.6

422.5

57.7

364.8

87.7

277.1

2.3

274.9

22.7%

2.7

31.9

152.8

357.7

43.4

314.3

75.5

237.0

-2.4

237.1

20.4%

2.3

Y-o-Y

4.1%

-13.1%

1.8%

17.8%

2.5%

-60 bps

41.6%

-25.7%

18.0%

33.1%

16.1%

16.4%

16.8%

15.9%

230 bps

15.7%

1,131.2

136.7

197.3

354.3

442.9

6.9%

13.6%

-0.9%

3.9%

10.8%

39.1%

150 bps

35.6

202.8

275.6

55.4

220.2

55.6

164.6

0.9

163.6

14.5%

1.6

27.0%

-44.0%

53.2%

4.1%

65.7%

58.0%

68.3%

152.9%

68.0%

820 bps

67.7%

Q3 FY23

Q-o-Q

FY23

FY22

4,592.2

4,623.7

588.8

785.0

715.0

706.6

1,398.4

1,165.2

Y-o-Y

-0.7%

-17.6%

11.1%

20.0%

1,820.0

2,036.9

-10.6%

39.6%

141.5

617.2

44.1%

128.3

526.9

1,344.3

1,638.3

209.5

164.5

1,134.9

1,473.8

283.2

851.7

5.8

846.3

18.4%

8.3

367.2

1,106.7

9.9

1,096.8

23.7%

10.8

-450 bps

10.3%

17.1%

-17.9%

27.3%

-23.0%

-22.9%

-23.0%

-41.7%

-22.8%

-530 bps

-23.0%

*Not annualized

Company Overview

Vijaya at a Glance

Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India with 121 state-of-the-art centres spread across 20 cities

Mission

Our Mission is to make the patient’s medical journey faster, more transparent and more accurate. We are committed to deliver exceptional diagnostic solutions to every patient and physician

40+ Years of Experience

Experience in delivering Quality Diagnostic Service at affordable prices

121 Centres

State-of-the-art Facilities with Best-in-class Technology

20 Cities across India

200+ Doctors

Vision

Largest integrated player in South India

Radiologists, Pathologists & Microbiologists

Our Vision is to provide reliable and accurate to our customers, at diagnostic services customer-centric in a affordable prices, manner. We strive to provide the best service possible. We are continually raising our own bar through the latest technology, continuous improvement and recruitment of high calibre technicians and professional

~3.2 Mn Footfalls

~10.1 Mn Tests

Trusted by every Age group

Most preferred Diagnostic Centre

Footfalls & Tests for 12 months ending Mar 2023

Quality

Reliable & Accurate Diagnostics

at Affordable Prices

Our Journey

Vijaya Diagnostic Centre incorporated in Hyderabad

Recognized as one of the Best Imaging centres in Hyderabad by The Week

Awarded Brand of the year in diagnostic services by The CEO Magazine and Telangana Healthcare Leadership award

One of the earliest private diagnostic service providers to be approved for COVID RT- PCR testing by ICMR*

Awarded one of the Best Healthcare Brands 2022 by The Economic Times

Won the Healthcare Leadership Awards 2022

Awarded Pride of India Brands Award – The Best of South Awards 2022

1981

2012

2018

2020

2022

2008

2016

2019

2021

First independent diagnostic centre in South India to offer PET CT from Wipro GE Healthcare Pvt. Ltd.

Investment by Karakoram Limited and Kedaara Capital Alternative Investment Fund – Kedaara Capital AIF1

Awarded Best Diagnostic Centre – India by Times Healthcare Achievers Group

Successfully listed on Indian Stock Exchanges (NSE & BSE)

First independent diagnostic centre in Telangana to get Revolution ACT 50 slice CT from Wipro GE Healthcare Pvt. Ltd

*ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange

At the Forefront of Introducing New Technologies

1981

Ultrasound & Echocardiography

1986

Nuclear Medicine facility

1993

Fourth Generation CT Scan

1994

Offer Mammography

2006

Hawkeye Gamma Camera with SPECT

2003

Automated Microbiology Culture

2000

Real Time RT-PCR Assays & Flow Cytometry

1999

Bone Densitometry

2007

Cardiac CT & 3.0 Tesla MRI

2009

HPV-DNA HC2 test in South India

2011

Automated TB identification & Sensitivity in South India

2012

Liquid Based Cytology (Thin Prep) in Andhra Pradesh (AP)

2019

3D Mammography with Advanced Technology

2019

USG-ECHO for Cardiology & Advanced CBCT in South India

2017

Droplet Digital PCR (ddPCR) & Adv. PET CT in South India

2013

iQ200 Automated Iris Urine with Analyzer Microscopy & Siemen’s Accuson Elastography

2019

DNA fragmentation Index test in semen

2020

Integrated modular solution for Immunoassay & Chemistry assays

2020

COVID testing by RT-PCR in Telangana & AP

2021

Philips DS Achieva with Ambient Experience

2022

‘Walk-in Walk-out Dual source CT’ and ‘BioMatrix 3T’

Our Pillars of Strength

One of the leading players in India’s high growth diagnostics market

Integrated diagnostics provider offering one-stop solution

High brand recall driving customer stickiness

Robust technical capabilities and state-of-the-art technology

Experienced Board and strong management team

Indian Diagnostics Market expected to Grow at a Healthy Trajectory

Indian Diagnostics Market

Segment-wise breakup of Indian Diagnostic Market

(INR Bn)

Radiology

Pathology

980

+13% CAGR

684

472

FY17

FY20

FY23E

+13% CAGR

FY23E 275 - 285

FY20 190 - 195

South India

27% - 29%

FY20

71%-73%

Rest of India

980

43% - 44%

684

43%

+13% - 14% CAGR

+14% CAGR

56% - 57%

+12% CAGR

57%

+12% - 13% CAGR

FY20

FY23E

472

41%

59%

FY17

Source: CRISIL Report

One of the leading players in India’s high growth diagnostics market

Telangana and Andhra Pradesh Market Size

Vijaya’s Core Geographies

Telangana and Andhra Pradesh (44 - 46% of South India)

+14% CAGR

(INR Bn)

120 -130

FY17

FY20

FY23E

Growth Drivers:

•

Rising NCDs in the states

Increasing share of aged population

Rising health awareness

Increasing health insurance penetration

Conducive government healthcare schemes

Dominant Position in Telangana & Andhra Pradesh

Nizamabad

Karimnagar

Mancherial

Hanamkonda Kazipet

Warangal

Sangareddy

Shamshabad

Shadnagar

Wanaparthy

Hyderabad & Secunderabad

Kurnool

Nandyal

Nellore

Tirupati

Vishakhapatnam

Rajahmundry

NCD: Non Communicable diseases

Source: CRISIL Report

Integrated Diagnostic service provider with extensive network…

Customers

Samples

Customer (Walk-in) Home Collection B2B Hospitals & Labs

Vijaya Diagnostic Centre

Flagship Centre #1

Hubs #28

Spokes #92

National Reference Lab

Reference Lab

#16

Sample Flow Patient Flow

Flagship Centre = Lab Sample Collection + Basic Radiology + Complete Advanced Radiology (MRI, CT Scan, SPECT & PET CT) Hubs = Lab Samples Collection + Basic Radiology + Advanced Radiology (MRI / CT Scan / SPECT) Spokes = Lab Samples Collection + Basic Radiology Basic Radiology = ECG / X-ray / USG / Mammography / BMD / TMT / 2D Echo / EEG / ENMG / Endoscopy, etc.

…offering One-Stop Solutions for Pathology & Radiology

Complete Range of Diagnostic Services under One Roof Comprehensive and high quality integrated diagnostic services through our operational network

High brand recall driving customer stickiness

Customer Centric Approach

Quality Diagnostic Services

B2C Revenue

Higher brand recall

High share of walk-in customers

Sticky individual customer

(INR)

“One of the Best Healthcare Brands 2021” by The Economic Times in 2021

“For excellence in Quality and Accuracy” under the category Leading Diagnostics company with Excellence in Quality and Safety at the Diagnostics Leadership Summit in 2021

95%

94%

93%

92%

90%

FY19

FY20

FY21

FY22

FY23

Operational Metrics

1,228

1,214

1,431

1,276

1,446

454

475

631

562

573

FY19

FY20

FY21

FY22

FY23

Revenue per footfall

EBITDA per footfall

Robust Technical Capabilities with State-of-the-art IT Infrastructure

CT Machines

MRI Machines

PET CT / Gamma machines

200+

Radiologists, Lab Doctors & Physicians

NABH Accreditations

NABL Accreditations

Key Suppliers

• Long standing relationship with medical technology vendors

• At the forefront of introducing new tests by

adopting the latest medical

technologies

• Among the first diagnostic service provider in South India to offer PET-CT scan

in 2008

Advanced Software to Manage Clinical Data

Advance Laboratory Information Management System (LIMS)

Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)

Front end IT infrastructure enabling…

Standardization across our operations

incidence

Reduce errors due Human Intervention

of Low

Monitor Operations

Technical

Closely track key performance metrics and maintain the Turn- Around Time (TAT)

Provide Uniform Experience to booking from customers accessing to appointments reports online

Doctors connect program

Vijaya Diagnostic Centre, in association with the North Andhra Orthopaedic Association, organized a Continuous (CPD) Professional program in Radiology in Visakhapatnam

Development

Vijaya Diagnostic Centre conducted a Continuing Medical Education (CME) on Radiology in Rajahmundry

Centre

Diagnostic

Vijaya and Homeopathic Medical Association of Telangana jointly organized the Dr. in Seshachary Memorial Oration Hyderabad

Vijaya Diagnostic Centre, in association with the IMA Mancherial Branch, organized Continuous Medical Education (CME) program in Radiology in Mancherial

Experienced Board of Directors

Dr. S Surendranath Reddy - Executive Chairman ▪ Founder of Vijaya with 40+ years of experience in building Vijaya as South

India’s largest integrated diagnostic chain

▪ Holds Bachelor’s degree in Medicine and Provisional degree of Doctor of

Medicine in Radiology

Dr. D Nageshwar Reddy - Non-executive, Independent Director

▪ Chairman of Asian Institute of Gastroenterology (AIG), Hyderabad ▪ Awarded Padma Shri and Padma Bhushan by Government of India ▪ D.M in Gastroenterology from PGIMER Chandigarh

S Geeta Reddy - Non-Executive Director

▪ Enrolled as advocate with Andhra Pradesh High Court in 1986

▪ Holds a Bachelor’s degree in Law from Osmania University

Shekhar Prasad Singh - Non-executive, Independent Director

▪ Ex-Chief Secretary to Government of Telangana

▪ Retired IAS officer of 1983 batch

Satyanaryana Murthy Chavali - Non-executive, Independent Director

▪ Ex-CEO of Aurigene Discovery Technologies Ltd.

▪ Holds BTech from IIT, Madras and MBA from IIM, Bangalore

Sunil Chandra Kondapally - Executive Director

▪ Been with Vijaya since 2002 and 17+ years of experience in healthcare

▪ Holds Bachelor’s degree in Electrical Engineering from Florida State

Dr. Manjula Anagani - Non-executive, Independent Director

University

▪ Clinical Director and Head of Department of centre of women and childcare at

Care hospitals

▪ Awarded Padma Shri by Government of India ▪ MD in Obstetrics and Gynecology from N.T.R. University of Health Sciences

Strong Management Team

Dr. S. Surendranath Reddy

Mr. Sunil Chandra Kondapally

Ms. Suprita Reddy

Mr. Narasimha Raju K.A

Executive Chairman

Executive Director

Chief Executive Officer

Chief Financial Officer

▪ 40+ years of experience in building Vijaya as South India’s integrated diagnostic largest chain

▪ Holds Bachelor’s degree in Provisional and Medicine degree of Doctor of Medicine in Radiology

▪ He is a life member of the and

Radiological

Indian Imaging Association.

▪ With Vijaya since incorporation and experienced in operations, finance, quality accreditation, marketing network expansion departments

and

▪ 17+ Years of experience in healthcare industry & founded Trikona Pharmaceuticals Pvt. Ltd. (2016) and QPS Bioserve India Pvt. Ltd. (2004)

operations

▪ With Vijaya since 2003 and heads overall strategy, clinical and excellence, expansion of the company ▪ Awarded Women Leadership Award in Healthcare by ABP in 2019

▪ Holds bachelors degree in from Osmania

commerce University

▪ Holds bachelor’s degree

electrical engineering Florida State University

in from

▪ Associated with Vijaya from June 2017 to Nov 2020 and rejoined in March 2021

▪ 14+ years of experience in reporting, financial and

audit, regulatory accounting advisory

compliance

▪ Previously worked with SR Baltliboi & Co., NSL Renewable Power Pvt. Ltd. etc

▪ Holds bachelor’s degree of commerce from Osmania University and member of the Chartered of Institute Accountants of India

Awards & Accolades

Most Trusted Brand of the Year 2023

Best Healthcare Brands 2022

Pride of India Brands Award 2022

One of the Best Healthcare Brands 2021

Indo Global Award for Healthcare Excellence

Company of the Year - Healthcare

2023 Presented by Marksmen Daily

2022 Presented by The Economic Times

2022 Presented by The Best of South Awards

2021 Presented by The Economic Times

2021 Presented by Indian Economic Development & Research Association

2021 Presented by TV9 Network and SAP

Leading Diagnostic Chain of the Year

India’s Greatest Brands 2020- 21 Pride of Nation

Leading Diagnostics with Excellence in Quality & Safety

Most Trusted and Best Quality Diagnostic services in India

Healthcare Entrepreneur of the Year – Dr. Surendra Reddy

2021 Presented by Diagnostic Leadership Summit

2021 Presented by United Research Services

2021 Presented by Diagnostic Leadership Summit

2020 Presented by Times Healthcare Achievers

2019 Presented by Six Sigma Healthcare

Fastest Growing Brands (Pride of the Nation)

Best Diagnostic Centre of the Year

Leading Chain of Diagnostics & Imaging

Best Diagnostic Service Provider of the Year

Most Trusted Diagnostic Centre of the Year

Telangana Healthcare Leadership Awards

2019 Presented by United Research Services

2019 Presented by Times Healthcare Achievers

2019 Presented by Indian Medical Association, Telangana state and Messe India

2019 Presented by Six Sigma Healthcare

2019 Presented by Indo-Arab Leaders Summit & Awards

2018 Presented by Telangana Government

Shareholding Pattern as of 31st Mar 2023

Others

FII’s

25.3%

13.9%

5.8%

DIIs

As on 31st March 2023 DII’s: Mutual Funds, AIF’s and QIB’s Others: Retail, Bodies Corporate and others

Promoter & Promoter group

55.0%

Marquee Institutional Investors

Wasatch Advisors

Aberdeen Standard Investments

Nippon Life India

Axis Mutual Fund

Fidelity Group

Abu Dhabi Investment Authority

DSP Healthcare Fund

Goldman Sachs

Strategy Going Forward

Deepen Footprint in our Core Markets - Telangana & Andhra Pradesh

Nizamabad

Sangareddy

Mancherial

Karimnagar

Hanamkonda Kazipet Warangal

Shamshabad Shadnagar

Wanaparthy

Kurnool Nandyal

Hyderabad & Secunderabad

Vishakhapatnam

Rajahmundry

Nellore

Tirupati

Leveraging Existing Presence

Given under-penetration of diagnostic market, we will continue to focus on

Opening additional diagnostic centres through owned model

Expanding network through setting up spokes and hubs in existing catchment areas

Adding reference laboratories in our existing core geographies

Consolidate Leading Position

Given our significant presence and operational experience in Telangana and Andhra Pradesh, we intend to deepen our penetration and increase customer base by

Enhancing laboratory capacity and test menu by adding latest technologies

Offering value added services

Physician engagements (by conducting continuous medical education programs)

Expand in Adjacent Geographies & East India

Network (FY22)

South India Strategy

◼ Expand in concentric circles given our

hub and spoke model

◼ Establish presence in adjacent

geographies

◼ Identified key cities and towns which are

underserved and our brand is well- regarded

◼ Wider geographic reach will expand our

customer base leading to better profitability by leveraging our infrastructure

Hyderabad

Rest of Telangana and AP

Others

East India Strategy

◼ Expand presence in East India given

growing demand

◼ Replicate our successful hub and spokes

model in East India

◼ Established a hub in Kolkata and plan is to

set up additional diagnostic centres around it

◼ Hence, Kolkata to be our focus area for

medium to long term growth

AP: Andhra Pradesh

Continued Focus on Providing Customer Centric Services and Offerings

Preventive and Wellness Testing to Boost Demand for Diagnostics

FY20E

Industry Size

FY23P

CAGR: ~20%

101-108

61-68

Rest of the market 90%

Wellness & Preventive 9% - 10%

Wellness & Preventive 11%

Rest of the market 89%

FY20

FY23

Key Drivers

Our Strategy

◼ Increasing chronic and lifestyle diseases

◼ Increase diagnostic services by offering additional preventive and wellness services through adoption of

new cutting-edge diagnostic testing technology

◼ Corporate tie-ups

◼ Increasing disposable income

◼ Increasing service offerings

◼ Providing home collection services and point-of-contact testing to complement walk-in

◼ Expand specialty tests, disease specific profiles and provide customized packages

◼ Grow our corporate customer base by catering to their needs

◼ Expansion of chronic disease management and wellness programs

Source: CRISIL Report

Financial & Operational Highlights

Robust Operational Metrics

Diagnostic Centre (Nos)

Footfalls (Mn)

Tests Performed (Mn)

121

3.62

3.18

2.79

2.63

2.38

10.05

9.32

6.99

7.91

7.09

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

Test per Footfall (Nos)

Revenue per Test (INR)

Revenue per Footfall (INR)

2.93

2.83

Impact of COVID-19

3.17

2.69

2.57

531

496

457

419

428

1,431

1,446

1,228

1,214

1,276

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

Consistent Financial Performance

(INR Mn)

Revenue

CAGR:12%

3,388

3,767

2,926

4,624

4,592

EBIDTA

CAGR:14%

2,037

1,820

1,660

1,326

1,081

PAT

CAGR:17%

1,097

845

846

625

459

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

EBIDTA Margin (%)

260 bps

44.1% 44.1%

39.1%

37.0%

39.6%

PAT Margin (%)

270 bps

18.5%

15.7%

22.4% 23.7%

18.4%

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

Note: Refer Slide no. 4

Sustainable Cash Generation & Increasing Return Ratios

Cash & Cash Equivalents

CFO / EBIDTA (%)

(INR Mn)

1,729

1,215

2,277

2,466

2,554

90%

84%

80%

78%

77%

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

RoCE Pre-Cash (%)

RoE (%) 1

43%

38%

30%

33%

25%

22%

23%

16%

FY19

FY20

FY21

FY22

FY23

FY19

FY20

FY21

FY22

FY23

ROCE (Pre-cash): PBIT ex Other income / (Total Assets – Cash – Current Liabilities)

Note 1: Refer Slide no. 4 CFO = Cash flow from Operations

Annexure

Consolidated Profit & Loss Account

(INR Mn)

Particulars

Revenue from operations

Cost of materials consumed

Employee benefits expense

Other expenses

EBITDA

EBITDA %

Other income

Depreciation and amortization expense

EBIT

Finance costs

Profit before Tax

Tax expenses

Profit after Tax before Minority Interest

Minority Interest

Profit after Tax

PAT %

EPS – Basic (INR)

Note: Refer Slide no. 4

FY23

4,592

589

785

1,398

1,820

39.6%

142

617

1,344

209

1,135

283

852

5.8

846

18.4%

8.29

FY22

4,624

715

707

1,165

2,037

44.1%

128

527

1,638

165

1,474

367

1,107

1,097

23.7%

10.76

FY21

3,767

571

574

962

1,660

44.1%

118

505

1,274

152

1,121

270

851

845

22.4%

8.28

FY20

3,388

439

624

999

1,326

39.1%

154

492

988

154

834

209

625

FY19

2,926

405

539

901

1,081

37.0%

104

396

789

135

653

190

463

459

18.5%

6.13

15.7%

4.50

Consolidated Balance Sheet

(INR Mn)

Assets NON-CURRENT ASSETS Property, plant and equipment Capital work-in-progress Goodwill Other intangible assets Right of use asset Intangible assets under development Financial assets - Investments - Other financial assets Deferred tax assets Income tax assets Other assets

Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 2,689 3,022 5,777 1,437 1,358 2,940 27 82 271 69 53 53 7 22 6 1,079 1,260 2,223 - 12 6

4,436 1,966 341 53 14 1,672 1

2,959 1,398 93 53 10 1,254 4

0 90 83 2 85

0 75 89 2 223

0 122 61 6 61

0 55 16 9 67

0 43 12 8 7

CURRENT ASSETS Inventories Financial assets - Investments - Trade receivables - Cash and cash equivalents - Bank balances other than Cash and cash equivalents - Loans - Other financial assets Other current assets

2,757 20

2,698 43

2,388 26

1,865 28

1,374 22

1390 95 242

542 98 110

276 64 67

922

1,813

1,876

0 51 41

0 52 27

36 51

547 80 556

626

1 5 22

688 91 96

430

4 26 17

EQUITY AND LIABILITIES

EQUITY

Equity share capital

Instruments entirely equity in nature

Other equity

Mar-23 Mar-22 Mar-21 Mar-20 Mar-19

5,466

4,695

3,592

2,741

2,069

102

5,364

4,593

3,547

2,696

2,000

NON-CURRENT LIABILITIES

2,406

1,778

1,377

1,494

1,422

Financial liabilities

- Borrowings

- Lease liabilities

- Other financial liabilities

Provisions

Other liabilities

CURRENT LIABILITIES

Financial liabilities

- Borrowings

- Lease liabilities

- Trade payables

- Other financial liabilities

Income tax liabilities

Provisions

Other liabilities

221

315

2,330

1,703

1,265

1,196

1,034

662

661

440

589

572

145

277

140

126

216

248

101

222

217

224

218

204

TOTAL ASSETS

8,534

7,135

5,409

4,824

4,063

TOTAL EQUITY AND LIABILITIES

8,534

7,135

5,409

4,824

4,063

Consolidated Cash Flow Statement

(INR Mn)

Particulars Cash Flow from Operating Activities Profit before Tax Adjustment for Non-Operating Items Operating Profit before Working Capital Changes Changes in Working Capital Cash Generated from Operations Less: Direct Taxes paid Net Cash from Operating Activities Purchase and construction of property, plant and building (net) Investments (net) Others Cash Flow from Investing Activities Cash Flow from Financing Activities Net increase/ (decrease) in Cash & Cash equivalent Cash & Cash Equivalents at the beginning of the period Cash & Cash equivalents at the end of the period

Cash and Cash Equivalents

Particulars

Investments*

Cash and cash equivalents

Bank balances other than Cash and cash equivalents

Total

Mar-23

Mar-22

Mar-21

Mar-20

Mar-19

1,135 683 1,818 90 1,908 -262 1,646 -1,248 734 887 -1,096 -419 131 110 242

Mar-23

1,390

242

922

2,554

1,474 572 2,046 -67 1,979 -399 1,580 -1,223 -127 120 -1,231 -306 44 67 110

1,121 534 1,655 -46 1,609 -312 1,297 -312 -1,033 47 -1,298 -488 -489 556 67

834 492 1,326 -32 1,294 -233 1,061 -375 11 57 -306 -295 460 96 556

653 431 1,084 8 1,092 -187 905 -591 -314 6 -898 -72 -65 161 96

Mar-22

Mar-21

Mar-20

Mar-19

542

110

1,813

2,465

335

1,876

2,277

547

556

626

1,729

688

430

1,215

*Current investments + investments with maturity more than 12 months (part of other non-current financial assets)

THANK YOU

Company

Investor Relations Advisors

Vijaya Diagnostic Centre Limited (VDCL)

Citigate Dewe Rogerson (CDR India)

Mr. Siva Rama Raju Head – Strategy & Investor Relations +91 99485 95555 / +91 90597 00749

sivaramaraju.v@vijayadiagnostic.in ir@vijayadiagnostic.in

www.vijayadiagnostic.com

Mr. Anoop Poojari / Mr. Devrishi Singh

Tel: +91 98330 90434 / +91 98205 30918

anoop@cdr-india.com devrishi@cdr-india.com

#6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India.

← All Transcripts VIJAYA Stock Page →

Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation

Market Movers